{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:18:45Z","timestamp":1775668725094,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejca.2021.12.011","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T04:57:30Z","timestamp":1639630650000},"page":"182-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article"],"prefix":"10.1016","volume":"162","author":[{"given":"J\u00e9r\u00f4me","family":"Barri\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Carles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoubir","family":"Adjtoutah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ejca.2021.12.011_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.011_bib2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","article-title":"Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19","volume":"12","author":"Wheatley","year":"2021","journal-title":"Nat Commun"},{"issue":"6561","key":"10.1016\/j.ejca.2021.12.011_bib3","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejca.2021.12.011_bib4","first-page":"21261496","article-title":"Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort","author":"Israel","year":"2021","journal-title":"medRxiv"},{"issue":"14","key":"10.1016\/j.ejca.2021.12.011_bib5","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJMc2112981","article-title":"Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce","volume":"385","author":"Keehner","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.011_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.annonc.2021.04.020","article-title":"Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients","volume":"32","author":"Palich","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.011_bib7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.011_bib8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.12.011_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2021.08.035","article-title":"COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy","volume":"157","author":"Cavanna","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.011_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2021.08.007","article-title":"Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy - a single centre prospective study","volume":"157","author":"Shmueli","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10282","key":"10.1016\/j.ejca.2021.12.011_bib11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO International Standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.011_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00247-21","article-title":"Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays","volume":"9","author":"Perkmann","year":"2021","journal-title":"Microbiol Spectr"},{"issue":"11","key":"10.1016\/j.ejca.2021.12.011_bib13","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2021.12.011_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/2159-8290.CD-20-1817","article-title":"Priority COVID-19 vaccination for patients with cancer while\u00a0vaccine supply is limited","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ejca.2021.12.011_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","article-title":"Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.12.011_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.09.035","article-title":"Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)","volume":"141","author":"Li\u00e8vre","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.011_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2021.06.008","article-title":"Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer","volume":"154","author":"Barri\u00e8re","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.011_bib18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Dul\u00e9ry","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.011_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","article-title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium","volume":"32","author":"Grivas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.12.011_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.07.002","article-title":"Severe COVID-19 in patients with hematological cancers presenting with viremia","author":"Michot","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.12.011_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.annonc.2021.01.068","article-title":"The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate","volume":"32","author":"Garassino","year":"2021","journal-title":"Monitor. Educate. Ann Oncol."},{"key":"10.1016\/j.ejca.2021.12.011_bib22","unstructured":"States must include patients with cancer on COVID-19 vaccine priority list february 17, 2021; Washington DC. Accessed February 19, 2021. https:\/\/www.asco.org\/about-asco\/press-center\/news-releases\/states-must-include-patients-cancer-covid-19-vaccine-priority."},{"key":"10.1016\/j.ejca.2021.12.011_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejca.2021.01.046","article-title":"SARS-CoV-2 vaccines for cancer patients: a call to action","volume":"148","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.011_bib24","first-page":"S0923","article-title":"Seroconversion rate after vaccination against COVID-19 in cancer patients-a systematic review","author":"Corti","year":"2021","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.011_bib25","first-page":"S0959","article-title":"Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","author":"Becerril-Gaitan","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.011_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2021.10.013","article-title":"Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis","volume":"159","author":"Tran","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2021.12.011_bib27","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.annonc.2021.06.018","article-title":"High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers","volume":"32","author":"Palich","year":"2021","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.011_bib28","article-title":"Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study","volume":"S0923-7534","author":"Nelli","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.011_bib29","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.ejca.2021.12.011_bib30","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ejca.2021.12.011_bib31","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.12.011_bib32","first-page":"1","article-title":"Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies","author":"Re","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.ejca.2021.12.011_bib33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.12.011_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2021.09.030","article-title":"Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment","volume":"159","author":"Buttiron Webber","year":"2021","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.011_bib35","article-title":"Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses","volume":"S1556-0864","author":"Gounant","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.12.011_bib36","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.annonc.2021.07.012","article-title":"Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients","volume":"32","author":"Heudel","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.12.011_bib37","series-title":"Vaccins contre la Covid-19: modalites d\u2019administration des rappels","year":"2021"},{"key":"10.1016\/j.ejca.2021.12.011_bib38","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.011_bib39","first-page":"S0085","article-title":"A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response","author":"Masset","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2021.12.011_bib40","doi-asserted-by":"crossref","unstructured":"Massa, Filippo and Cremoni, Marion and Gerard, Alexandre and Grabsi, Hanen and Rogier, Lory and Blois, Mathilde, et\u00a0al, Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients. Available at: SSRN: https:\/\/ssrn.com\/abstract=3890865 or https:\/\/doi.org\/10.2139\/ssrn.3890865.","DOI":"10.2139\/ssrn.3890865"},{"key":"10.1016\/j.ejca.2021.12.011_bib41","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","author":"Hall","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.12.011_bib42","article-title":"Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients with lymphoid malignancies","author":"Re","year":"2021","journal-title":"Preprint, Research Square"},{"issue":"10","key":"10.1016\/j.ejca.2021.12.011_bib43","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1016\/S2352-3026(21)00274-X","article-title":"Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT","volume":"8","author":"Redjoul","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2021.12.011_bib44","series-title":"Establishment of the WHO international standard and reference panel for antiSARS-CoV-2 antibody","year":"2020"},{"issue":"9","key":"10.1016\/j.ejca.2021.12.011_bib45","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.011_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J Exp Med"},{"issue":"9767","key":"10.1016\/j.ejca.2021.12.011_bib47","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0140-6736(10)62228-3","article-title":"Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"377","author":"Barrett","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.011_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the advisory Committee on immunization practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"issue":"7847","key":"10.1016\/j.ejca.2021.12.011_bib49","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.12.011_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.12.011_bib51","first-page":"21261290","article-title":"Immune assays team; moderna, inc. Team; coronavirus vaccine prevention network (CoVPN)\/Coronavirus efficacy (COVE) team; United States government (USG)\/CoVPN biostatistics team. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial","author":"Gilbert","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ejca.2021.12.011_bib52","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2021.12.011_bib53","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-021-01355-0","article-title":"Delayed production of neutralizing antibodies correlates with fatal COVID-19","volume":"27","author":"Lucas","year":"2021","journal-title":"Nat Med"},{"issue":"7867","key":"10.1016\/j.ejca.2021.12.011_bib54","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.12.011_bib55","doi-asserted-by":"crossref","first-page":"103561","DOI":"10.1016\/j.ebiom.2021.103561","article-title":"Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection","volume":"71","author":"Gallais","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2021.12.011_bib56","doi-asserted-by":"crossref","first-page":"100861","DOI":"10.1016\/j.eclinm.2021.100861","article-title":"SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy","volume":"35","author":"Abu-Raddad","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"7871","key":"10.1016\/j.ejca.2021.12.011_bib57","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.12.011_bib58","article-title":"Systemic COVID-19 vaccination also enhances the humoral immune response after SARS CoV-2 infection. An approach to criteria for COVID-19 re-immunization is needed. Do we need a third dose?","author":"Kosiorek","year":"2021","journal-title":"ResearchSquare"},{"key":"10.1016\/j.ejca.2021.12.011_bib59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijid.2021.08.052","article-title":"Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose","volume":"112","author":"Vicenti","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.011_bib60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2021.12.011_bib61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2021.05.036","article-title":"High levels of anti-SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine","volume":"154","author":"Fong","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.011_bib62","first-page":"21262111","article-title":"Large-scale study of antibody titre decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection","author":"Israel","year":"2021","journal-title":"medRxiv [Preprint]"},{"key":"10.1016\/j.ejca.2021.12.011_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection\u00a0against symptomatic and asymptomatic SARS-CoV-2 infection","author":"Feng","year":"2021","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.011_bib64","article-title":"Antibody titres and protection against a SARS-CoV-2 infection","volume":"S0163-S4453","author":"Dimeglio","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.ejca.2021.12.011_bib65","article-title":"Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMO","author":"Kertes","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ejca.2021.12.011_bib66","series-title":"Convalescent plasma EUA letter of authorization 06032021","year":"2021"},{"issue":"9","key":"10.1016\/j.ejca.2021.12.011_bib67","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","article-title":"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers","volume":"9","author":"Lustig","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.011_bib68","article-title":"Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study","volume":"S1198-743X","author":"Buonfrate","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.011_bib69","volume":"11","author":"Lee","year":"2021","journal-title":"BMJ Open"},{"issue":"21","key":"10.1016\/j.ejca.2021.12.011_bib70","article-title":"Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan","volume":"S1198-743X","author":"Kageyama","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.011_bib71","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/diagnostics11040593","article-title":"Five commercial immunoassays for SARS-CoV-2 antibody determination and their comparison and correlation with the virus neutralization test","volume":"11","author":"\u0160im\u00e1nek","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.011_bib72","doi-asserted-by":"crossref","first-page":"e02104","DOI":"10.1128\/JCM.02104-20","article-title":"Comparison of the clinical performances of the Abbott alinity IgG, Abbott Architect IgM, and Roche Elecsys total SARS-CoV-2 antibody assays","volume":"59","author":"Harley","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ejca.2021.12.011_bib73","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13632","article-title":"Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection","author":"Perkmann","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejca.2021.12.011_bib74","first-page":"21256246","article-title":"Is WHO international standard for anti-SARS-CoV-2 immunoglobulin clinically useful?","author":"Lukaszuk","year":"20210429","journal-title":"medRxiv"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.011_bib75","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3390\/diagnostics11081496","article-title":"Quantitative SARS-CoV-2 spike antibody response in COVID-19 patients using three fully automated immunoassays and a surrogate virus neutralization test","volume":"11","author":"Kim","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ejca.2021.12.011_bib76","first-page":"21262426","article-title":"The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study","author":"Perkmann","year":"20210826","journal-title":"medRxiv"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.011_bib77","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41591-021-01435-1","article-title":"A French cohort for assessing COVID-19 vaccine responses in specific populations","volume":"27","author":"Loubet","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.12.011_bib78","first-page":"21262468","article-title":"Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers","author":"Tober-Lau","year":"20210826","journal-title":"medRxiv"},{"issue":"10","key":"10.1016\/j.ejca.2021.12.011_bib79","article-title":"SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63","volume":"131","author":"Woldemeskel","year":"2021","journal-title":"J\u00a0ClinInvest"},{"key":"10.1016\/j.ejca.2021.12.011_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.03.033","article-title":"Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients","volume":"150","author":"Mansi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7870","key":"10.1016\/j.ejca.2021.12.011_bib81","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:51Z","timestamp":1760733351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":81,"alternative-id":["S0959804921012752"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}